Triptorelin vs Vesilute
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
Tissue-specific dipeptide bioregulator (Glu-Asp) that epigenetically normalizes urogenital function through chromatin remodeling, anti-inflammatory cytokine regulation, and smooth muscle tone restoration in the bladder and prostate
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Triptorelin
11.25–11.25 mg
Vesilute
2–2 capsules
Frequency
Triptorelin
Once daily
Vesilute
Once daily
Administration
Triptorelin
Intramuscular injection
Vesilute
Oral (capsule/tablet)
Cycle length
Triptorelin
Ongoing/indefinite
Vesilute
12+ weeks
Onset speed
Triptorelin
Moderate (1-2 weeks)
Vesilute
Gradual (3-4 weeks)
Evidence level
Triptorelin
Strong human trials (Phase 3 or FDA approved)
Vesilute
Moderate human trials (Phase 1-2)
Benefit ratings
Hormone Regulation
Cancer Management
Endometriosis Relief
Bladder Health
Prostate Support
Tissue Repair
Compound specifications
Triptorelin
Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
Half-life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS number
57773-63-4
Vesilute
Molecular formula
C9H14N2O7
Molecular weight
262.2 g/mol
Half-life
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids via standard pathways
Bioavailability
High oral bioavailability for a dipeptide — absorbed intact by intestinal peptide transporter PepT1 (SLC15A1); ultra-short structure enables efficient cellular uptake and nuclear penetration
CAS number
3918-84-1
Dosing compared
Triptorelin
Intramuscular injection
3.75 mg
Once every 4 weeks · Ongoing while indicated
FDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
11.25 mg
Once every 12 weeks · Ongoing while indicated
FDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
22.5 mg
Once every 24 weeks · Ongoing while indicated
FDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].
Vesilute
Oral (capsule/tablet)
1 capsule (10 mg) once daily
Once daily before meals · 10-day initial course
Khavinson ED (Glu-Asp) urogenital dipeptide bioregulator; absorbed intact via PepT1 transporter [6]. Research/wellness use, not FDA-approved.
2 capsules (20 mg) daily
1–2 times daily before meals · 20–30 day course
Standard daily dose; courses repeated every 2–6 months [6]. Sublingual administration also used for buccal uptake.
Subcutaneous injection
10–20 mg per week (split into 2–3 injections)
2–3 times weekly · 20–30 day course
Injectable practice protocol for direct systemic delivery of the ED dipeptide [6]. Research use only.
Best suited for
Triptorelin
Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Vesilute
Supporting bladder health and urinary function in aging individuals
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic urogenital inflammation through epigenetic mechanisms
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing standard urological treatments with peptide bioregulator therapy
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Triptorelin
Vesilute
Common
- Mild gastrointestinal discomfort
- Increased urinary frequency initially
- Mild headache
- Minor fatigue
Uncommon
- Injection site irritation
Serious
- No documented serious adverse effects
Safety & evidence
Triptorelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- Pregnancy (can affect fetal development)
- Undiagnosed vaginal bleeding
- Known hypersensitivity to GnRH agonists
- Severe untreated depression
- Active spinal cord compression in prostate cancer (requires urgent decompression)
Vesilute
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin. Limited systemic absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature. Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active urinary tract infection requiring antibiotic treatment — treat infection first
- Bladder or prostate malignancy — proliferative effects of peptide bioregulators may be contraindicated
Which is right for you?
Choose Triptorelin if...
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation
Choose Vesilute if...
- Supporting bladder health and urinary function in aging individuals
- Bioregulatory approach to benign prostatic hyperplasia (BPH) management
- Reducing chronic urogenital inflammation through epigenetic mechanisms
- Complementing standard urological treatments with peptide bioregulator therapy